Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab in Episodic Cluster Headache (ALLEVIATE)
NCT04688775Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of eptinezumab in Cluster Headache (CH), sponsored by Lundbeck. Started Dec 2020; status: completed.
02
Drugs
eptinezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT04688775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688775.